Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal
Takeda is bringing two Phase II narcolepsy trials to a premature end in the aftermath of a “safety signal.”
The trials tested TAK-994 as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
